Show simple item record

Files in this item

Thumbnail

Item metadata

dc.contributor.authorRothe, Camilla
dc.contributor.authorSloan, Derek J.
dc.contributor.authorGoodson, Patrick
dc.contributor.authorChikafa, Jean
dc.contributor.authorMukaka, Mavuto
dc.contributor.authorDenis, Brigitte
dc.contributor.authorHarrison, Tom
dc.contributor.authorvan Oosterhout, Joep J.
dc.contributor.authorHeyderman, Robert S.
dc.contributor.authorLalloo, David G.
dc.contributor.authorAllain, Theresa
dc.contributor.authorFeasey, Nicholas A.
dc.date.accessioned2018-03-27T14:30:05Z
dc.date.available2018-03-27T14:30:05Z
dc.date.issued2013-06-28
dc.identifier.citationRothe , C , Sloan , D J , Goodson , P , Chikafa , J , Mukaka , M , Denis , B , Harrison , T , van Oosterhout , J J , Heyderman , R S , Lalloo , D G , Allain , T & Feasey , N A 2013 , ' A prospective longitudinal study of the clinical outcomes from cryptococcal meningitis following treatment induction with 800 mg oral fluconazole in Blantyre, Malawi ' , PLoS One , vol. 8 , no. 6 , e67311 . https://doi.org/10.1371/journal.pone.0067311en
dc.identifier.issn1932-6203
dc.identifier.otherPURE: 241921233
dc.identifier.otherPURE UUID: 33e47fe5-496b-4f5c-9274-cf2283834557
dc.identifier.otherScopus: 84879515411
dc.identifier.otherPubMed: 23840659
dc.identifier.otherORCID: /0000-0002-7888-5449/work/60631038
dc.identifier.urihttps://hdl.handle.net/10023/13032
dc.descriptionDr. Feasey was supported by a Wellcome Research Training Fellowship and MLW is funded by a Wellcome Trust Major Overseas Project Grant (award number 084679/Z/08/Z).en
dc.description.abstractIntroduction:Cryptococcal meningitis is the most common neurological infection in HIV infected patients in Sub Saharan Africa, where gold standard treatment with intravenous amphotericin B and 5 flucytosine is often unavailable or difficult to administer. Fluconazole monotherapy is frequently recommended in national guidelines but is a fungistatic drug compromised by uncertainty over optimal dosing and a paucity of clinical end-point outcome data.Methods:From July 2010 until March 2011, HIV infected adults with a first episode of cryptococcal meningitis were recruited at Queen Elizabeth Central Hospital, Blantyre, Malawi. Patients were treated with oral fluconazole monotherapy 800 mg daily, as per national guidelines. ART was started at 4 weeks. Outcomes and factors associated with treatment failure were assessed 4, 10 and 52 weeks after fluconazole initiation.Results:Sixty patients were recruited. 26/60 (43%) died by 4 weeks. 35/60 (58.0%) and 43/56 (77%) died or failed treatment by 10 or 52 weeks respectively. Reduced consciousness (Glasgow Coma Score 3 of 5) and confusion (Abbreviated Mental Test Score
dc.format.extent6
dc.language.isoeng
dc.relation.ispartofPLoS Oneen
dc.rights© 2013 Rothe et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.en
dc.subjectRA0421 Public health. Hygiene. Preventive Medicineen
dc.subjectAgricultural and Biological Sciences(all)en
dc.subjectBiochemistry, Genetics and Molecular Biology(all)en
dc.subjectMedicine(all)en
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subject.lccRA0421en
dc.titleA prospective longitudinal study of the clinical outcomes from cryptococcal meningitis following treatment induction with 800 mg oral fluconazole in Blantyre, Malawien
dc.typeJournal articleen
dc.description.versionPublisher PDFen
dc.contributor.institutionUniversity of St Andrews. School of Medicineen
dc.identifier.doihttps://doi.org/10.1371/journal.pone.0067311
dc.description.statusPeer revieweden


This item appears in the following Collection(s)

Show simple item record